Loading company…
NMD Pharma develops small molecule therapies for neuromuscular diseases, targeting the ClC-1 ion channel in skeletal muscle.
Founded in 2015 and headquartered in Aarhus, Denmark, NMD Pharma A/S develops treatments for neuromuscular disorders such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease and sarcopenia. Its lead molecule, NMD670, is a first-in-class ClC-1 inhibitor in Phase 2 studies. The company raised EUR 75 million in a Series B round on November 15, 2023, led by Jeito Capital, with Novo Holdings and Roche Venture Fund also investing. Thomas Pedersen is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in